The day before, the State Food and Drug Administration (now the national market supervision bureau) issued the "2017 annual drug review report" (hereinafter referred to as the "report"). The report shows that the reform of China's drug review and approval system has played an important role in encouraging drug innovation and improving the quality of drugs. In 2015, the State Council issued "on the reform of drug and medical device review and approval system", put forward 12 reform tasks; in 2017, the office of the State Office issued "on deepening the review and approval system reform to encourage medical opinion" innovative drugs, put forward 36 suggestions to encourage drug innovation. "In the past three years, the reform of the review and approval system for drug review has made great achievements." Sun Xianze, director of the Chinese Pharmaceutical Association, pointed out. The backlog of drug application is safe and effective, and it is the basic requirement for the drug. It is also the original intention of the review and approval of the drug review. But in the past period of time, the problem of low efficiency of drug trial and slow listing of drugs has plagued a wide range of problems.